Inclusion Criteria:

- Histologic documentation of primary lung carcinoma, non-squamous histology with EGFR
mutation Negative.

- Stage IIIB/IV disease according to the 7th Edition of the American Joint Committee on
Cancer staging system

- Not received radiotherapy, chemotherapy or other biological treatment

- Measureable disease

- Life expectancy of >= 12 months

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

- Absolute neutrophil count (ANC) >= 2, 500/mm^3

- Platelet count >= 100,000/mm^3

- Hemoglobin >= 9.0 g/dL

- Total bilirubin =< 1.5 x upper limit of normal (ULN)

- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and
serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x
ULN in patients without liver or bone metastases; < 5 x ULN in patients with liver or
bone metastases

- Cockcroft-Gault calculated creatinine clearance of >= 45 ml/min or creatinine =< 1.5
x ULN

- Prothrombin time (PT) =< 1.5 x ULN

- Partial thromboplastin time (PTT) =< ULN

- Urine dipstick proteinuria < 2+ * Note: Patients discovered to have >= 2 +
proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine
collection and must demonstrate < 1 g of protein in 24 hours

- Negative pregnancy test done =< 7 days prior to randomization, for women of
childbearing potential only

- Provide informed written consent

- Willing to return to Sichuan cancer hospital for follow-up

- Willing to provide tissue and blood samples for correlative research purposes

Exclusion Criteria:

- Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a
predominant squamous component

- Prior chemotherapy or treatment for metastatic non-small cell lung cancer

- Immunocompromised patients (other than that related to the use of corticosteroids)
including patients known to be human immunodeficiency virus (HIV) positive, per MD
discretion

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Receiving any other investigational agent which would be considered as a treatment
for the primary neoplasm

- Other active malignancy =< 3 years prior to randomization; EXCEPTIONS: Non melanotic
skin cancer or carcinoma-in-situ of the cervix

- History of myocardial infarction or other evidence of arterial thrombotic disease
(angina)

- History of cerebral vascular accident (CVA) or transient ischemic attack (TIA) =< 6
months prior to randomization

- Ongoing or active infection, symptomatic congestive heart failure , cardiac
arrhythmia, psychiatric illness/social situations, or any other medical condition
that would limit compliance with study requirements

- History of bleeding diathesis or coagulopathy

- Inadequately controlled hypertension (systolic blood pressure of > 150 mmHg or
diastolic pressure > 100 mmHg on anti-hypertensive medications)

- Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical
procedure, open biopsy, or significant traumatic injury =< 28 days or core biopsy =<
7 days prior to randomization

- History of abdominal fistula, gastrointestinal perforation, or intrabdominal abscess
=< 6 months prior to randomization

- History of hemoptysis >= grade 2 (defined as bright red blood of at least 2.5 mL) =<
3 months prior to randomization

- Pregnancy